Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioengineering
Bavarian Nordic - Strengthens Commercial Focus; Pipeline Update
October 5th, 2007
Bavarian Nordic, the Danish-based biopharmaceutical company, announced it will establish a new separate sales and marketing function to strengthen the company's commercial activities and increase marketing efforts on its third-generation smallpox vaccine, IMVAMUNE(R) as well as future HIV and cancer vaccines. The new commercial affairs function will be headed up by an Executive Vice President who will join the Corporate Management group and refer to Anders Hedegaard, CEO. An appointment is expected before year-end. Bavarian Nordic sees great potential in the market for IMVAMUNE smallpox vaccine, as evidenced by the recent contract award(i) by the Department of Health...
Source: Health Business Week (2007-10-05)
|
